Equities

Kopran Ltd

KOPRAN:NSI

Kopran Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)323.40
  • Today's Change-2.30 / -0.71%
  • Shares traded682.35k
  • 1 Year change+42.47%
  • Beta0.6999
Data delayed at least 15 minutes, as of Sep 20 2024 11:25 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in INRIncome statement in INRView more

Year on year Kopran Ltd grew revenues 11.54% from 5.51bn to 6.15bn while net income improved 87.11% from 272.33m to 509.56m.
Gross margin36.03%
Net profit margin9.31%
Operating margin11.42%
Return on assets--
Return on equity--
Return on investment--
More ▼

Cash flow in INRView more

In 2024, Kopran Ltd increased its cash reserves by 9.39%, or 6.95m. The company earned 432.58m from its operations for a Cash Flow Margin of 7.04%. In addition the company generated 9.89m cash from financing while 435.52m was spent on investing.
Cash flow per share17.14
Price/Cash flow per share21.44
Book value per share--
Tangible book value per share--
More ▼

Balance sheet in INRView more

Kopran Ltd uses little or no debt in its capital structure.
Current ratio--
Quick ratio--
Total debt/total equity--
Total debt/total capital--
More ▼

Growth rates in INR

Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items increased 87.11%. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
Div yield(5 year avg)1.57%
Div growth rate (5 year)--
Payout ratio (TTM)24.40%
EPS growth(5 years)13.73
EPS (TTM) vs
TTM 1 year ago
211.81
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.